Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), DDR1 antagonists(Discoidin domain receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 14 Jul 2023 | |
Melanoma | Phase 1 | CN | 14 Jul 2022 | |
Breast Cancer | Phase 1 | CN | 30 Jan 2022 | |
Breast Cancer | Phase 1 | US | 30 Jan 2022 | |
Colorectal Cancer | Phase 1 | US | 30 Jan 2022 | |
Pancreatic Cancer | Phase 1 | US | 30 Jan 2022 | |
Stomach Cancer | Phase 1 | US | 30 Jan 2022 | |
Stomach Cancer | Phase 1 | CN | 30 Jan 2022 | |
Giant Cell Tumor of Tendon Sheath | IND Approval | CN | 14 Jul 2022 |
Phase 1 | - | cyuijiubth(rkmmpywizb) = lcwyoauppc pjycmcidit (bjpcgkkjzf ) View more | - | 02 Jun 2022 |